Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clomiphene citrate + urofollitropin is a combination therapy used in the management of female infertility, particularly for ovulation induction and controlled ovarian stimulation. Clomiphene citrate is an orally administered selective estrogen receptor modulator (SERM) that stimulates the release of gonadotropins (FSH and LH) from the pituitary by blocking estrogen receptors in the hypothalamus, leading to increased follicular development and ovulation[4][6][7][8]. Urofollitropin is a purified form of human follicle-stimulating hormone (FSH), typically administered via subcutaneous injection, which directly stimulates ovarian follicular growth[5]. This combination may be used sequentially or together in women who do not respond adequately to clomiphene alone or as part of assisted reproductive technologies such as in vitro fertilization. The primary indication is for women with anovulatory infertility, including those with polycystic ovary syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomiphene citrate + urofollitropin.